Skip to main content
SpringerLink
Log in

Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Although subclinical hyperthyroidism (SCH) has been associated with increased risk of osteoporosis and cardiac arrhythmias, its treatment is still controversial. This study was designed as a prospective, randomized, intervention, control-study with a 1-year follow-up in order to investigate whether normalization of serum TSH in SCH using methimazole has favorable bone and heart clinical effects. Fourteen patients with endogenous SCH (not Graves’ disease) were enrolled, 7 (5 women/2 men; group T) were treated with methimazole (2.5–7.5 mg/day), and 7 (5 women/2 men; group C) were followed without treatment; 10 healthy subjects were also included in the study as controls. Serum free-T3 (FT3), free-T4 (FT4) and TSH, thyroid echography, bone stiffness index (SI), as measured by heel ultrasonometry, and 24-h electrocardiography monitoring were obtained. SCH patients exhibited higher systolic and diastolic blood pressure than control subjects. They also had a significantly higher number of both ventricular premature beats (VPB) (mean±SEM: 681 ±238 vs 6±2 beats/24 h; p<0.02) and atrial premature beats (APB) (mean±SEM: 495±331 vs 7±2 beats/24 h; p<0.0001), and a lower SI (66±5 vs 96±3; p<0.001). Twelve months after normalization of TSH with the use of methimazole, the number of VPB decreased significantly (947±443 vs 214±109 beats/24 h; p<0.05) while it remained unchanged in untreated SCH patients (414±163 vs 487±152 beats/24 h; p=ns). An insignificant therapy effect was observed as far as APB were concerned (826±660 vs 144±75 beats/24 h; p=ns), however their number increased significantly in the untreated group (463±49 vs 215±46 beats/ 24 h; p<0.05). The SI increased significantly as a result of therapy in group T (64.1 ±4.8 vs 70.0±5.3; p<0.02) and was further reduced in group C at the end of the study (69.1 ±7.3 vs 62.9±7.1; p<0.001 ). No adverse effect was observed in group T. In conclusion, anti-thyroid therapy seems to have favorable bone and heart clinical effects in subjects with endogenous SCH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Helfand M. Screening for subclinical thyroid dysfunction in non-pregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004, 140: 128–41.

    Article  PubMed  Google Scholar 

  2. Toft AD. Subclinical hyperthyroidism. N Engl J Med 2001, 345: 512–6.

    Article  PubMed  CAS  Google Scholar 

  3. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol 2000, 53: 733–7.

    Article  CAS  Google Scholar 

  4. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001, 358: 861–5.

    Article  PubMed  CAS  Google Scholar 

  5. Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995, 43: 55–68.

    Article  CAS  Google Scholar 

  6. Helfand M, Redfern CC. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann Intern Med 1998, 129: 144–58.

    Article  PubMed  CAS  Google Scholar 

  7. AACE Thyroid Task Force. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002, 8: 458–67.

    Google Scholar 

  8. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 2004, 291: 228–38.

    Article  PubMed  CAS  Google Scholar 

  9. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetric analysis of thyroid lobes by real-time ultrasound. Deutsche Medizinische Wochenschrift 1981, 106: 1338–40.

    Article  PubMed  CAS  Google Scholar 

  10. Greenspan SL, Bouxsein ML, Melton ME, et al. Precision and discriminatory ability of calcaneal bone assessment technologies. J Bone Miner Res 1997, 12: 1303–13.

    Article  PubMed  CAS  Google Scholar 

  11. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996, 348: 511–4.

    Article  PubMed  CAS  Google Scholar 

  12. Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986, 314: 1676–86.

    Article  PubMed  CAS  Google Scholar 

  13. Lee WY, Oh KW, Rhee EJ, et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 2006, 37: 511–6.

    Article  PubMed  CAS  Google Scholar 

  14. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994, 41: 421–4.

    Article  CAS  Google Scholar 

  15. Kisakol G, Kaya A, Gonen S, Tunc R. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003, 50: 657–61.

    Article  PubMed  CAS  Google Scholar 

  16. Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999, 9: 539–43.

    Article  PubMed  CAS  Google Scholar 

  17. Yönem O, Dökmetas HS, Aslan SM, Erselcan T. Is antithyroid treatment really relevant for young patients with subclinical hyperthyroidism? Endocr J 2002, 49: 307–14.

    Article  PubMed  Google Scholar 

  18. Britto JM, Fenton AJ, Holloway WR, Nicolson GC. Osteoclast mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994, 134: 169–76.

    PubMed  CAS  Google Scholar 

  19. Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986, 7: 379–408.

    Article  PubMed  CAS  Google Scholar 

  20. Inoue M, Tawata M, Yokomori N, Endo T, Onaya T. Expression of thyrotropin receptor on clonal osteoblast-like rat osteosarcoma cells. Thyroid 1998, 8: 1059–64.

    Article  PubMed  CAS  Google Scholar 

  21. Kumeda Y, Inaba M, Tahara H, et al. Persistent increase in bone turnover in Graves’ patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000, 85: 4157–61.

    PubMed  CAS  Google Scholar 

  22. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk of fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001, 134: 561–8.

    Article  PubMed  CAS  Google Scholar 

  23. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994, 331: 1249–52.

    Article  PubMed  CAS  Google Scholar 

  24. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001, 142: 838–42.

    Article  PubMed  CAS  Google Scholar 

  25. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001, 344: 501–9.

    Article  PubMed  CAS  Google Scholar 

  26. Sgarbi JA, Villaça FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003, 88: 1672–7.

    Article  PubMed  CAS  Google Scholar 

  27. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2000, 85: 4701–5.

    PubMed  CAS  Google Scholar 

  28. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993, 87: 1435–41.

    Article  PubMed  CAS  Google Scholar 

  29. Klein I, Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest 1986, 77: 1694–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  30. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease. Clinical applications. JAMA 2004, 291: 239–43.

    Article  PubMed  CAS  Google Scholar 

  31. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 2001, 145; 391–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cardiovascular and Kidney Diseases, Faculty of Medicine, University of Palermo; U.O. of AUSL6, Palermo, Italy

    S. Buscemi MD, S. Verga, S. Cottone, G. Andronico & G. Cerasola

  2. Internal Medicine AUSL6, Partinico Hospital, AUSL6, Palermo, Italy

    L. D’Orio

  3. Department of Cardiology, Partinico Hospital, AUSL6, Palermo, Italy

    V. Mannino

  4. Department of Orthopedics, Partinico Hospital, AUSL6, Palermo, Italy

    D. Panzavecchia

  5. Department of Clinical Chemistry, Partinico Hospital, AUSL6, Palermo, Italy

    F. Vitale

Authors
  1. S. Buscemi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Verga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Cottone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Andronico
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. D’Orio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Mannino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Panzavecchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Cerasola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Buscemi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buscemi, S., Verga, S., Cottone, S. et al. Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism. J Endocrinol Invest 30, 230–235 (2007). https://doi.org/10.1007/BF03347430

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347430

Key Words

Search

Navigation